亿帆医药：在研项目F-652的ACLF、AH适应症均于2021年后才取得II期临床批件

Group 1 - The core viewpoint of the article is that Yifan Pharmaceutical has provided updates on its clinical projects, specifically F-652, indicating that the clinical approval for indications ACLF and AH was obtained after 2021 [2] Group 2 - The company responded to investor inquiries on its interactive platform regarding the status of its research projects [2]